Marinus Pharmaceuticals Q3 2023 Earnings Report $0.55 0.00 (-0.16%) As of 02/11/2025 Earnings HistoryForecast Marinus Pharmaceuticals EPS ResultsActual EPS-$0.61Consensus EPS -$0.67Beat/MissBeat by +$0.06One Year Ago EPSN/AMarinus Pharmaceuticals Revenue ResultsActual Revenue$7.34 millionExpected Revenue$6.54 millionBeat/MissBeat by +$800.00 thousandYoY Revenue GrowthN/AMarinus Pharmaceuticals Announcement DetailsQuarterQ3 2023Date11/7/2023TimeN/AConference Call ResourcesPress ReleaseMRNS Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Marinus Pharmaceuticals Earnings HeadlinesStockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)February 17, 2025 | americanbankingnews.comMarinus Pharmaceuticals (NASDAQ:MRNS) Acquisition Completed by Immedica Pharma ABFebruary 13, 2025 | americanbankingnews.com9/9 on TSLA from June to JanuaryPlease take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!February 22, 2025 | Wealthpin Pro (Ad)Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stockFebruary 11, 2025 | msn.comMarinus Pharmaceuticals director sells shares worth $869January 24, 2025 | msn.comMarinus pharmaceuticals director sells shares for $864January 24, 2025 | msn.comSee More Marinus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Marinus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marinus Pharmaceuticals and other key companies, straight to your email. Email Address About Marinus PharmaceuticalsMarinus Pharmaceuticals (NASDAQ:MRNS), a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.View Marinus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
